F-star Therapeutics, an invoX company, has announced a strategic collaboration and license agreement with Takeda to discover and develop next-generation multi-specific antibodies. The collaboration will focus on using F-star's proprietary platforms to research and develop immunotherapies for cancer patients.
Under the agreement, F-star and Takeda will work together to research and develop novel Fcab domains against undisclosed immuno-oncology targets. Takeda will have exclusive rights to commercialize antibodies incorporating Fcab domains arising from the collaboration, while F-star retains certain other Fcab domains.
As part of the agreement, F-star will receive upfront payment, research funding, and potential milestone payments of up to $1 billion if all milestones are reached. Additionally, they will receive royalties on any commercial products resulting from the license.
Neil Brewis, Head of F-star Therapeutics and Chief Scientific Officer, expressed excitement about expanding their relationship with Takeda and developing innovative immunotherapies for cancer patients.